{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06215911",
            "orgStudyIdInfo": {
                "id": "CRD-750-201"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508736-62",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Cardurion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)",
            "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction",
            "acronym": "Cycle-1-REF",
            "therapeuticArea": [
                "Cardiovascular",
                "Other"
            ],
            "study": "a-study-to-assess-safety-effectiveness-of-tovinontrine-in-chronic-heart-failure-with-reduced-ejection-fraction-cycle-ref"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-13",
            "studyFirstSubmitQcDate": "2024-01-19",
            "studyFirstPostDateStruct": {
                "date": "2024-01-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cardurion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure",
                "Heart Failure With Reduced Ejection Fraction",
                "Cardiovascular Diseases",
                "Heart Diseases"
            ],
            "keywords": [
                "PDE9",
                "PED9 Inhibitor",
                "Heart Failure",
                "CRD-750",
                "Tovinontrine",
                "HFrEF"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 400,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tovinontrine (CRD-750) - low dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Tovinontrine (CRD-750)"
                    ]
                },
                {
                    "label": "Tovinontrine (CRD-750) - medium dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Tovinontrine (CRD-750)"
                    ]
                },
                {
                    "label": "Tovinontrine (CRD-750) - high dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Tovinontrine (CRD-750)"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tovinontrine (CRD-750)",
                    "description": "Tablets administered orally",
                    "armGroupLabels": [
                        "Tovinontrine (CRD-750) - high dose",
                        "Tovinontrine (CRD-750) - low dose",
                        "Tovinontrine (CRD-750) - medium dose"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Tablets administered orally",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in biomarkers from Baseline to Week 12 - NT-proBNP",
                    "description": "The percent change in plasma NT-proBNP (Dose Cohort 3 versus placebo) will be calculated from Baseline to Week 12 using an ANCOVA model. If a statistically significant reduction in plasma NT-proBNP is detected (2-sided alpha=0.05), the next analysis will compare Dose 2 versus placebo at the (2-sided alpha = 0.05 level). If statistically significant, the next analysis will compare Dose 1 versus placebo.",
                    "timeFrame": "Baseline to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in biomarkers at Week 12 by treatment group - NT-proBNP",
                    "description": "The percent change in plasma NT-proBNP will be calculated by treatment group from Baseline to Week 12. The correlation of plasma concentration with percent change in plasma NT-proBNP will be evaluated using Pearson's correlation coefficient.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in biomarkers at week 12 by treatment group - cGMP",
                    "description": "The percent change in urine and plasma cGMP from Baseline to Week 12 will be analyzed using ANCOVA and MMRM models by treatment group.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in biomarkers at week 12 by treatment group - BNP",
                    "description": "The percent change in BNP from Baseline to Week 12 will be analyzed using an ANCOVA model to evaluate individual dose comparisons.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in the biomarker ratio at Week 12 - NT-proBNP",
                    "description": "The change in the urine and plasma cGMP to NT-proBNP ratio at week 12 will be calculated for each treatment group",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in the biomarker ratio at Week 12 - BNP",
                    "description": "The percent change in the urine and plasma cGMP to BNP ratio from Baseline to Week 12 will be calculated for each treatment group",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Kansas City Cardiomyopathy Questionnaire-23-Clinical Summary Score",
                    "description": "Scaled 0 to 100 where lower scores represent worse health status than higher scores",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Kansas City Cardiomyopathy Questionnaire 23- Overall Summary Score",
                    "description": "Scaled 0 to 100 where lower scores represent worse health status than higher scores",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "New York Heart Association Classification",
                    "description": "Class I to IV are possible with a higher classification representing worsening heart failure status",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Treatment Emergent Adverse Events (TEAEs)",
                    "description": "The number of participants with TEAEs including drug related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation will be assessed. The incidence of AEs will be presented by system organ class and preferred term according to the Medical Dictionary of Regulatory Activities.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in laboratory assessments",
                    "description": "Number of participants with normal/ abnormal values at Baseline compared to normal/ abnormal values post-Baseline will be assessed for hematology, serum chemistry and urinalysis. Descriptive statistics of clinical laboratory assessment results and the change from Baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in vital sign measurement: systolic and diastolic blood pressure",
                    "description": "Change from Baseline to Week 12 will be assessed for systolic and diastolic blood pressure (mmHg). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in vital sign measurement: pulse rate",
                    "description": "The change from Baseline to Week 12 will be assessed for pulse rate (bpm). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in vital sign measurement: respiratory rate",
                    "description": "The change from Baseline to Week 12 will be assessed for respiratory rate (breaths/min). Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in vital sign measurement: body temperature",
                    "description": "The change from Baseline to Week 12 will be assessed for body temperature. Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in physical examination",
                    "description": "General physical exams will be carried out to detect any abnormalities in the cardiovascular, respiratory, and other body systems. Non-pre-existing abnormal physical examinations will be summarized by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Changes in 12-lead electrocardiogram (ECG) measurements",
                    "description": "Number of participants who have normal/abnormal 12-lead ECG measurements at Baseline will be compared to normal/abnormal 12-lead ECG measurement post Baseline. Descriptive statistics of 12-lead ECG data and the change from baseline will be presented by dose cohort and visit.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Assessment of pharmacokinetics (PK): PK effect on NT-proBNP",
                    "description": "The plasma concentrations will be evaluated in the PK Population. The plasma concentration of tovinontrine will be summarized by dose cohort and visit. The correlation of plasma concentration with percent change in plasma NT-proBNP will be evaluated using Pearson's correlation coefficient.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Assessment of pharmacokinetics (PK): PK effect on plasma cGMP",
                    "description": "The plasma concentrations will be evaluated in the PK Population. The plasma concentration of tovinontrine will be summarized by dose cohort and visit. The correlation of plasma concentration with percent change in plasma cGMP will be evaluated using Pearson's correlation coefficient.",
                    "timeFrame": "Baseline to Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Is an adult male or female patient 18 years of age\n* Has evidence in the medical history supporting a diagnosis of clinical HF syndrome, NYHA functional class II to III, with the duration of at least 6 months prior to the time of Screening. The HF syndrome is defined by documentation of 1 or more of the following:\n\n  * At least 1 of the typical symptoms due to HF such as dyspnea and/or fatigue limiting exercise capacity;\n  * At least 1 of the typical signs of HF such as peripheral edema, elevated jugular venous pressure, pulmonary crackles; or\n  * Hospitalization, emergency department visit, or outpatient visit for HF requiring intravenous (IV) or subcutaneous (SQ) diuresis within the past 12 months.\n* Has ejection fraction (EF) \u2264 40% by transthoracic echocardiogram (TTE) performed and interpreted locally at the time of Screening;\n* Has NT-proBNP level \u2265 600 pg/mL at the time of Screening. Patients with atrial fibrillation or flutter at the time of Screening are required to have an NT-proBNP level of \u2265 1000 pg/mL at the time of Screening;\n* Is on stable optimized doses of guideline-directed HF therapy, per Investigator's clinical judgement, for a minimum of 4 weeks prior to the time of Screening and during Screening, with no planned changes after randomization.\n* Has had no addition of new guideline-directed HF therapy within the 3 months prior to the time of Screening or during the Screening Period;\n\nExclusion Criteria:\n\n* Has a documented EF \\>40% by TTE within 6 months of the time of Screening or during the Screening Period;\n* Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 60 days of the time of Screening or during the Screening Period;\n* Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration;\n* Has elective interventions (eg, percutaneous coronary intervention, device implantations, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study;\n* Has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, or carotid angioplasty within 60 days of the time of Screening or during the Screening Period;\n* Has had a prior or planned orthotopic heart transplantation;\n* Has presence of or plan for mechanical circulatory support;\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gail Berman",
                    "role": "CONTACT",
                    "phone": "617-863-8088",
                    "email": "Info@cardurion.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gail Berman",
                    "affiliation": "Senior VP Head, Clinical Development Cardurion",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35233",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90211",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Van Nuys",
                    "state": "California",
                    "zip": "91405",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.18667,
                        "lon": -118.44897
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32216",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33137",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Hazel Crest",
                    "state": "Illinois",
                    "zip": "60429",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.5717,
                        "lon": -87.69449
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Peoria",
                    "state": "Illinois",
                    "zip": "61636",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.69365,
                        "lon": -89.58899
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Alexandria",
                    "state": "Louisiana",
                    "zip": "71301",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 31.31129,
                        "lon": -92.44514
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Covington",
                    "state": "Louisiana",
                    "zip": "70433",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.47549,
                        "lon": -90.10042
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73135",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "McKinney",
                    "state": "Texas",
                    "zip": "75069",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.19762,
                        "lon": -96.61527
                    }
                },
                {
                    "facility": "Cardurion Investigative Site",
                    "status": "RECRUITING",
                    "city": "Chicoutimi",
                    "state": "Quebec",
                    "zip": "G7H 7K9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 48.41963,
                        "lon": -71.06369
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "asFound": "Heart Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}